As the first Myriad employee, I know from experience that social responsibility has been ingrained in the DNA of our culture since our earliest days – and
that commitment lives on today. In fiscal year 2014, we added to our legacy of good corporate citizenship through a combination of philanthropy and

Last year, we gave more than $13.7 million to help patients in financial need and to support the communities where we work and live. This is an increase of
25 percent compared to fiscal year 2013. About 95 percent of our total philanthropy is driven by free and subsidized molecular diagnostic testing offered
through our patient financial assistance programs.

Here are some highlights of our giving this year:

  • More than 4,000 people received assistance in paying for their diagnostic tests through our financial-assistance programs.
  • We donated $295,000 in cash to support key patient advocacy organizations where we have the ability to make a positive difference in addressing complex
    health challenges, increase education about diagnostic testing, and improve the quality of life for patients.
  • We provided $185,000 in financial support for academic scholarships at the undergraduate and post-graduate levels, and regularly contribute to advancing
    women and minorities in medicine and science.
  • Myriad provided $98,000 in financial support to nonprofit organizations and shared the expertise of our employees in the communities where we operate.

I’m proud that our employees are such good advocates of corporate responsibility. We know that this is a journey and will continue to strive for even
higher levels of performance and positive impact through our business and in our communities. In the meantime, we invite you to learn more about our
commitment to our patients and the quality products and services we offer at:


Pete Meldrum

CEO, Myriad Genetics, Inc.

Myriad Genetics at J.P. Morgan Healthcare Conference

Paul J. Diaz, president and chief executive officer, Bryan Riggsbee, chief financial officer, and Dale Muzzey, chief scientific officer, presented at the 41st annual J.P. Morgan (JPM) Healthcare Conference.